论文部分内容阅读
目的:检测乳腺癌组织中趋化因子受体5(CCR5)和c-erbB-2的表达情况,分析CCR5与c-erbB-2及腋窝淋巴结转移的关系。方法:采用免疫组化SP法检测72例乳腺癌组织标本中CCR5和c-erbB-2的表达,结合临床资料进行统计学分析。结果:72例乳腺癌组织标本中有61例(84.7%)CCR5表达阳性,其中伴有淋巴结转移者46例;CCR5与腋窝淋巴结转移(χ2=4.982,P=0.026)和c-erbB-2过度表达(χ2=4.583,P<0.05)均呈正相关。结论:CCR5可作为乳腺癌发生、发展及判断预后的一种新型的生物学标志。
Objective: To detect the expression of chemokine receptor 5 (CCR5) and c-erbB-2 in breast cancer and to analyze the relationship between CCR5 and c-erbB-2 and axillary lymph node metastasis. Methods: The expression of CCR5 and c-erbB-2 in 72 cases of breast cancer specimens was detected by immunohistochemical SP method. The clinical data were used for statistical analysis. Results: CCR5 was positive in 61 (84.7%) of 72 breast cancer specimens, of which 46 cases were associated with lymph node metastasis; CCR5 and axillary lymph node metastasis (χ2 = 4.982, P = 0.026) and c-erbB- Expression (χ2 = 4.583, P <0.05) were positively correlated. Conclusion: CCR5 can be used as a new biological marker for the occurrence, development and prognosis of breast cancer.